STOCK TITAN

Zynex Inc - ZYXI STOCK NEWS

Welcome to our dedicated news page for Zynex (Ticker: ZYXI), a resource for investors and traders seeking the latest updates and insights on Zynex.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zynex's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zynex's position in the market.

Rhea-AI Summary
Zynex, Inc. (ZYXI) to Participate in Benzinga's Pharma Companies vs. A Tough Macro Backdrop Free Webinar
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
conferences
-
Rhea-AI Summary
Zynex, Inc. (ZYXI) Reports 22% Revenue Increase to $45.0 Million in Q2 2023; EPS $0.09
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
-
Rhea-AI Summary
Zynex, Inc. will hold a conference call on July 27, 2023, at 4:15 PM Eastern Time to discuss its financial results for Q2 2023. The company specializes in non-invasive medical devices for pain management, rehabilitation, and patient monitoring. Dial-in numbers and webcast link provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
-
Rhea-AI Summary
Zynex, Inc. has engaged MZ Group to lead their strategic investor relations and financial communications program. MZ will work with Zynex to increase the company's visibility and deliver the investment opportunity to a broader audience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
News
Rhea-AI Summary
Zynex, Inc. has announced a $10.0 million share buyback program, which will commence on June 14, 2023, and is scheduled to terminate on June 13, 2024. The company aims to invest in itself while returning value to shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.21%
Tags
buyback
-
Rhea-AI Summary
Zynex, Inc. has announced the pricing of its private offering of $52.5 million convertible senior notes due 2026. The offering was upsized from the previously announced size of $50.0 million. The Notes Offering is expected to close on May 9, 2023. Zynex estimates that the net proceeds from the offering will be approximately $50.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.65%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.65%
Tags
Zynex Inc

Nasdaq:ZYXI

ZYXI Rankings

ZYXI Stock Data

380.28M
15.72M
51.14%
31.25%
18%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Englewood

About ZYXI

zynex, inc. founded in 1996, engineers, manufactures and markets neuro-diagnostics, stroke rehabilitation, pain management and cardiac monitoring devices within three subsidiaries. zynex medical is a provider of electrotherapy products for home use. zynex monitoring solutions develops products for cardiac monitoring for use in hospitals. zynex neurodiagnostics develops devices for emg and eeg diagnostic applications within neurology disciplines. zynex medical's product line is fully developed, fda/ce cleared, commercially sold, and has been developed to uphold the company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. zynex monitoring solutions and zynex neurodiagnostics are currently both in the development stages without any significant revenues.